Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate inhalation - Novartis/Sosei R&D

Next Previous
Drug Profile

Glycopyrrolate inhalation - Novartis/Sosei R&D

Alternative Names: AD-237; Enurev Breezhaler; Inhaled glycopyrrolate; Inhaled glycopyrronium bromide; NVA-237; Seebri Breezhaler; Seebri Inhalation Capsules; Seebri Neohaler; SeebriBreezhaler; Tovanor Breezhaler

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arakis Ltd; Vectura
  • Developer Novartis; Sumitomo Pharma America
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 23 Jun 2022 Phase-II clinical trials in Asthma (In children) in Spain, Hungary (Inhalation) (EudraCT2021-004972-32) (NCT05222529)
  • 04 Feb 2022 Novartis plans a phase II trial for Asthma (In children) in undisclosed locations (Inhalation, Powder) in May 2022 (NCT05222529) (EudraCT2021-004972-32)
  • 05 Jan 2022 Covis Pharma entered into a Distribution Agreement with Novartis Pharmaceuticals Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top